(Accepted 19 April 1985) IgM and IgG antibodies to human T cell lymphotropic retrovirus (HTLV-III) in lymphadenopathy syndrome and subjects at risk for AIDS in Italy F AIUTI, P ROSSI, M C SIRIANNI, M CARBONARI, M POPOVIC, M G SARNGADHARAN, L CONTU, M MORONI, S ROMAGNANI, R C GALLO Abstract A study was performed to assess the prevalence of specific antibodies to human T cell lymphotropic retrovirus (HTLV-Ill) in patients with lymphadenopathy syndrome, patients with the acquired immune deficiency syndrome (AIDS), and those at risk of AIDS. Serum samples were obtained from these groups and from healthy controls in selected cities in Italy, and antibodies to HTLV-Ill were measured by immunofluorescence assay and, in a few patients, by Western blotting. In addition, IgM antibody values were measured in 82 of those positive for HTLV-IU. Altogether, 235 out of 320 patients with lymphadenopathy syndrome had antibodies to HTLV-III, the proportions being highest in haemophiliacs, homosexuals, and drug addicts from Rome; 11 out of 12 patients with AIDS had antibodies; 78 out of 439 subjects at risk for AIDS had antibodies; and six out of 30 patients with lymphadenopathy syndrome and positive for HTLV-Ill antibodies and nine of 52 patients at risk of AIDS had a detectable titre of IgM.
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Discussion
In this study the prevalence of antibodies to HTLV-III in groups at risk for AIDS was higher than might be expected from the low incidence of AIDS in the population. We cannot explain this, but the observation supports the hypothesis that HTLV-III infection is widespread in groups at risk for AIDS in Italy. The proportions of patients with lymphadenopathy syndrome who were positive for antibodies varied, possibly due to the fact that serum samples were collected at different stages of the disease and from different geographical areas. Furthermore, that the infection still seems to be absent in small towns may be due to the low diffusion of HTLV-III infection among drug addicts in areas far away from large cities.
Compared with studies in other countries, such as Britain,' we found a higher proportion of apparently healthy intravenous drug abusers who were positive for antibodies. This may also be explained by the difference in spread of infection among geographical areas-see, for example, Milan and Catanzaro (table)-compared with Britain.
To our knowledge, all previous studies have been based on the detection of IgG antibodies.' -4 We are the first to report that a significant proportion of cases have IgM antibodies to HTLV-III, suggesting the possibility of recent infection. Furthermore, the overall prevalence of IgM antibodies was similar in patients with lymphadenopathy syndrome and subjects in the at risk group. This latter finding appears to provide evidence for a primary antibody response to a recently acquired HTLV-III infection, as in diseases similar to mononucleosis.'
In conclusion, our studies show that despite the small number of cases of AIDS seen in Italy since 1981 there is a high prevalence of antibodies to HTLV-III among patients with lymphadenopathy syndrome. This suggests that HTLV-III may have entered Italy as a result of spread in the United States and, therefore, that we might expect to see more cases of AIDS in Italy. These results support the idea that HTLV-III "infection" is spread mainly in compromised hosts, since none of the controls were positive for the antibodies.
